The foundations of immune checkpoint blockade and the ipilimumab approval decennial
AJ Korman, SC Garrett-Thomson… - Nature Reviews Drug …, 2022 - nature.com
Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …
discussion and experimentation for over a hundred years. Several successful cancer …
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
(PD-1)/programmed cell death-ligand 1 (PD-L1) are two most representative immune …
[HTML][HTML] Nasopharyngeal carcinoma ecology theory: Cancer as multidimensional spatiotemporal “unity of ecology and evolution” pathological ecosystem
W Luo - Theranostics, 2023 - ncbi.nlm.nih.gov
Nasopharyngeal carcinoma (NPC) is a particular entity of head neck cancer that is generally
regarded as a genetic disease with diverse intertumor and intratumor heterogeneity. This …
regarded as a genetic disease with diverse intertumor and intratumor heterogeneity. This …
Regulation and function of the PD-L1 checkpoint
Expression of programmed death-ligand 1 (PD-L1) is frequently observed in human
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
cancers. Binding of PD-L1 to its receptor PD-1 on activated T cells inhibits anti-tumor …
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
W Fang, Y Yang, Y Ma, S Hong, L Lin, X He… - The Lancet …, 2018 - thelancet.com
Background Platinum-based doublet chemotherapy regimens, preferentially gemcitabine
plus cisplatin, are generally considered the first-line standard of care for patients with …
plus cisplatin, are generally considered the first-line standard of care for patients with …
Nivolumab for relapsed/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: a single-arm, phase II study
SM Ansell, MC Minnema, P Johnson… - Journal of Clinical …, 2019 - ascopubs.org
Purpose Treatment options are limited for patients with relapsed/refractory diffuse large B-
cell lymphoma (DLBCL). Tumor cells can exploit the programmed death-1 checkpoint …
cell lymphoma (DLBCL). Tumor cells can exploit the programmed death-1 checkpoint …
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm …
A Younes, A Santoro, M Shipp, PL Zinzani… - The lancet …, 2016 - thelancet.com
Background Malignant cells of classical Hodgkin's lymphoma are characterised by genetic
alterations at the 9p24. 1 locus, leading to overexpression of PD-1 ligands and evasion of …
alterations at the 9p24. 1 locus, leading to overexpression of PD-1 ligands and evasion of …
Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study
AM Lesokhin, SM Ansell, P Armand, EC Scott… - Journal of clinical …, 2016 - ascopubs.org
Purpose Cancer cells can exploit the programmed death-1 (PD-1) immune checkpoint
pathway to avoid immune surveillance by modulating T-lymphocyte activity. In part, this may …
pathway to avoid immune surveillance by modulating T-lymphocyte activity. In part, this may …
Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI …
Purpose This multinational study evaluated the antitumor activity of nivolumab in
nasopharyngeal carcinoma (NPC). Tumor and plasma-based biomarkers were investigated …
nasopharyngeal carcinoma (NPC). Tumor and plasma-based biomarkers were investigated …
Current strategies to target tumor-associated-macrophages to improve anti-tumor immune responses
Established evidence demonstrates that tumor-infiltrating myeloid cells promote rather than
stop-cancer progression. Tumor-associated macrophages (TAMs) are abundantly present at …
stop-cancer progression. Tumor-associated macrophages (TAMs) are abundantly present at …